Back

ICD benefit in hypertrophic cardiomyopathy: a real-world analysis

10 May 2026 (11:30 - 12:30)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease - hypertrophic cardiomyopathy (2) Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Mr Diogo Ferreira

Santa Maria Hospital - CHULN, Lisbon (Portugal)

8 More presentations in this session

Presentation thumbnail
Impact of hypertrophic cardiomyopathy on work productivity and activity impairment in patients with HCM: analysis of a real-world cross-sectional survey
Doctor P. Gebrehiwet (South San Francisco, US)
Abstract Slides
Presentation thumbnail
Hypertrophic cardiomyopathy and fabry disease: right ventricular to pulmonary artery coupling can differentiate both?
Doctor A. Castro Pinto (Guimaraes, PT)
Abstract Slides
Presentation thumbnail
Validating prediction models for hypertrophic cardiomyopathy genotype positivity
Mr P. Kopp (Stony Brook, US)
Abstract Slides
Presentation thumbnail
Effectiveness and safety of mavacamten in obstructive hypertrophic cardiomyopathy in the real world: one-year data from the multicentre MARVEL.HU study
Doctor R. Sepp (Szeged, HU)
Abstract Slides
Presentation thumbnail
Heart failure profile in hypertrophic cardiomyopathy
Doctor N. Przytula (Krakow, PL)
Abstract Slides

Access the full session

Session thumbnail
ePosters in myocardial disease - hypertrophic cardiomyopathy (2)

The Event

Event poster

Heart Failure 2026

10 May 2026 11:30 CET
You may be interested in
thumbnail
Congress Presentation
Long-term outcomes associated with subcutaneous implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy
9 April 2024
thumbnail
Congress Session
Gaps in risk stratification for patients with structural heart disease
31 March 2025
thumbnail
Congress Presentation
Phenotypic predictors of pathogenic variants in probands with hypertrophic cardiomyopathy
28 August 2022
thumbnail
Congress Presentation
Cost-effectiveness of implantable cardioverter defibrillator for the primary prevention of sudden death
1 July 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources